{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sickle+Cell+Anemia+%28HbSS%2C+or+HbS%CE%B2-thalassemia0%29",
    "query": {
      "condition": "Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 4,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T08:18:51.715Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07175051",
      "title": "Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)",
        "Albuminuria"
      ],
      "interventions": [
        {
          "name": "Empagliflozin (oral)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Illinois at Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 20,
      "start_date": "2026-04-08",
      "completion_date": "2030-10",
      "has_results": false,
      "last_update_posted_date": "2026-05-19",
      "last_synced_at": "2026-05-22T08:18:51.715Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07175051"
    },
    {
      "nct_id": "NCT06647979",
      "title": "Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sickle Cell Disease",
        "Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)",
        "Beta-Thalassemia",
        "Transfusion Dependent Beta-Thalassaemia"
      ],
      "interventions": [
        {
          "name": "autologous bone marrow derived CD34+ HSPCs electroporated with BCL11A enhancer targeting Cas9 ribonucleoprotein",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sequencing Assay for Variant rs114518452",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DEVICE"
      ],
      "sponsor": "Daniel Bauer",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "13 Years to 40 Years"
      },
      "enrollment_count": 10,
      "start_date": "2025-12-01",
      "completion_date": "2030-12",
      "has_results": false,
      "last_update_posted_date": "2026-02-03",
      "last_synced_at": "2026-05-22T08:18:51.715Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06647979"
    },
    {
      "nct_id": "NCT06743113",
      "title": "Hypoxic Red Blood Cells in Sickle Cell Anemia",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sickle Cell Anaemia",
        "Sickle Cell Anemia Crisis",
        "Sickle Cell Anemia in Children",
        "Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)"
      ],
      "interventions": [
        {
          "name": "Hemanext ONE System",
          "type": "DEVICE"
        },
        {
          "name": "Conventional RBCs",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Hemanext",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "7 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2026-03",
      "completion_date": "2028-09",
      "has_results": false,
      "last_update_posted_date": "2026-01-07",
      "last_synced_at": "2026-05-22T08:18:51.715Z",
      "location_count": 6,
      "location_summary": "Farmington, Connecticut • St. Petersburg, Florida • Atlanta, Georgia + 2 more",
      "locations": [
        {
          "city": "Farmington",
          "state": "Connecticut"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06743113"
    },
    {
      "nct_id": "NCT01960413",
      "title": "Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)"
      ],
      "interventions": [
        {
          "name": "Montelukast added to Hydroxyurea",
          "type": "DRUG"
        },
        {
          "name": "Placebo added to Hydroxyurea",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "16 Years to 70 Years"
      },
      "enrollment_count": 46,
      "start_date": "2013-11",
      "completion_date": "2018-03",
      "has_results": true,
      "last_update_posted_date": "2019-03-26",
      "last_synced_at": "2026-05-22T08:18:51.715Z",
      "location_count": 2,
      "location_summary": "Nashville, Tennessee • Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01960413"
    }
  ]
}